Urogen Pharma (URGN) Stock Price

Urogen Pharma Price

NASDAQ·CLOSED
48.22USD+0.10 (+0.21 %)
Market closed

Over the last 9 years Urogen Pharma grew revenue by 22.6% annually, reaching 109.79 M USD. For Urogen Pharma, the net margin of -139.8% is up versus -230.7% a few years ago. The consensus 12-month price target for Urogen Pharma is 34.68 USD, about 28.1% below where the stock trades today. Of 14 analysts, 12 rate the stock a buy — an overall Buy consensus. The stock trades about 194% above its 52-week low.

Urogen Pharma stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Urogen Pharma over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Urogen Pharma stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Urogen Pharma's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Urogen Pharma Stock Price History
DateUrogen Pharma Price
8/14/202648.22 USD
8/13/202648.12 USD
8/12/202648.16 USD
8/10/202646.31 USD
8/7/202646.96 USD
8/6/202645.60 USD
8/5/202645.24 USD
8/4/202639.46 USD
8/3/202638.59 USD
7/31/202638.24 USD
7/30/202641.09 USD
7/29/202640.31 USD
7/27/202640.72 USD
7/23/202642.50 USD
7/22/202642.06 USD
7/21/202643.78 USD
7/20/202641.12 USD
7/17/202640.23 USD
7/16/202640.00 USD
7/15/202639.80 USD
7/14/202639.19 USD
7/13/202638.65 USD
7/10/202638.56 USD
7/9/202640.23 USD
7/8/202637.71 USD
7/7/202637.75 USD
7/6/202637.71 USD
7/2/202638.02 USD
7/1/202637.94 USD
6/30/202636.80 USD
6/29/202634.71 USD
6/26/202634.54 USD
6/25/202634.38 USD
6/24/202635.42 USD
6/23/202635.15 USD
6/22/202634.99 USD
6/18/202633.57 USD
6/17/202632.81 USD
6/16/202631.95 USD
6/15/202630.86 USD
6/12/202629.72 USD
6/11/202629.50 USD
6/10/202627.90 USD
6/5/202626.85 USD
6/4/202627.60 USD
6/3/202626.60 USD
6/2/202626.54 USD
6/1/202627.03 USD
5/29/202628.13 USD
5/28/202628.69 USD
5/27/202629.33 USD
5/26/202629.46 USD
5/22/202628.89 USD
5/21/202629.88 USD
5/20/202630.22 USD
5/19/202628.26 USD
5/14/202629.68 USD
5/13/202630.94 USD
5/4/202623.29 USD
5/1/202623.00 USD
4/30/202623.83 USD
4/29/202623.34 USD
4/28/202624.12 USD
4/27/202623.77 USD
4/24/202624.11 USD
4/23/202624.31 USD
4/22/202626.06 USD
4/21/202625.03 USD
4/20/202624.92 USD
4/17/202622.54 USD
4/16/202621.39 USD
4/15/202621.51 USD
4/14/202621.22 USD
4/13/202620.28 USD
4/10/202621.57 USD
4/9/202620.53 USD
4/8/202619.10 USD
4/7/202618.03 USD
4/6/202618.61 USD
4/2/202618.82 USD
4/1/202618.94 USD
3/31/202617.98 USD
3/30/202617.00 USD
3/27/202617.17 USD
3/26/202617.90 USD
3/25/202618.12 USD
3/24/202617.66 USD
3/23/202617.30 USD
3/20/202617.62 USD
3/19/202618.59 USD
3/18/202618.48 USD
3/17/202618.59 USD
3/16/202618.73 USD
3/13/202618.44 USD
3/12/202618.79 USD
3/11/202618.84 USD
3/10/202619.45 USD
3/9/202619.91 USD
3/6/202620.46 USD
3/5/202619.61 USD
3/4/202620.16 USD
3/3/202618.82 USD
3/2/202619.02 USD
2/27/202621.70 USD
2/26/202621.18 USD
2/25/202620.67 USD
2/24/202620.75 USD
2/23/202620.92 USD
2/20/202621.07 USD
2/19/202621.80 USD
2/18/202622.27 USD
2/17/202620.60 USD
2/13/202620.10 USD
2/12/202620.21 USD
2/11/202621.14 USD
2/10/202621.67 USD
2/9/202621.90 USD
2/6/202621.35 USD
2/5/202620.52 USD
2/4/202620.71 USD
2/3/202620.00 USD
2/2/202619.70 USD
1/30/202619.61 USD
1/29/202620.69 USD
1/28/202621.32 USD
1/27/202621.85 USD
1/26/202621.08 USD
1/23/202620.00 USD
1/22/202620.00 USD
1/21/202619.23 USD
1/20/202619.33 USD
1/16/202618.80 USD
1/15/202619.54 USD
1/14/202618.74 USD
1/13/202619.83 USD
1/12/202621.45 USD
1/9/202621.25 USD
1/8/202623.47 USD
1/7/202623.14 USD
1/6/202621.89 USD
1/5/202622.13 USD
1/2/202622.71 USD
12/31/202523.42 USD
12/30/202523.17 USD
12/29/202523.33 USD
12/26/202523.03 USD
12/24/202523.76 USD
12/23/202523.40 USD
12/22/202523.58 USD
12/19/202522.80 USD
12/18/202521.72 USD
12/17/202522.62 USD
12/16/202523.47 USD
12/15/202522.85 USD
12/12/202521.80 USD
12/11/202522.36 USD
12/10/202522.19 USD
12/9/202522.70 USD
12/8/202523.08 USD
12/5/202522.98 USD
12/4/202524.28 USD
12/3/202524.35 USD
12/2/202524.38 USD
12/1/202528.46 USD
11/28/202528.81 USD
11/26/202529.42 USD
11/25/202527.69 USD
11/24/202526.93 USD
11/21/202525.87 USD
11/20/202524.84 USD
11/19/202525.27 USD
11/18/202523.55 USD
11/17/202523.70 USD
11/14/202523.76 USD
11/13/202523.92 USD
11/12/202525.14 USD
11/11/202523.63 USD
11/10/202523.13 USD
11/7/202523.24 USD
11/6/202523.54 USD
11/5/202519.31 USD
11/4/202519.81 USD
11/3/202520.62 USD
10/31/202520.47 USD
10/30/202519.85 USD
10/29/202519.78 USD
10/28/202520.18 USD
10/27/202520.85 USD
10/24/202518.97 USD
10/23/202517.33 USD
10/22/202517.66 USD
10/21/202518.14 USD
10/20/202518.00 USD
10/17/202516.95 USD
10/16/202516.93 USD
10/15/202517.29 USD
10/14/202516.65 USD
10/13/202516.76 USD
10/10/202516.68 USD
10/9/202516.42 USD
10/8/202517.33 USD
10/7/202516.84 USD
10/6/202517.05 USD
10/3/202517.40 USD
10/2/202517.07 USD
10/1/202517.82 USD
9/30/202519.95 USD
9/29/202519.14 USD
9/26/202518.34 USD
9/25/202517.26 USD
9/24/202517.99 USD
9/23/202517.88 USD
9/22/202517.99 USD
9/19/202517.95 USD
9/18/202518.87 USD
9/17/202518.10 USD
9/16/202518.07 USD
9/15/202518.06 USD
9/12/202518.79 USD
9/11/202519.25 USD
9/10/202519.11 USD
9/9/202520.69 USD
9/8/202521.42 USD
9/5/202518.88 USD
9/4/202518.80 USD
9/3/202519.37 USD
9/2/202519.53 USD
8/29/202519.45 USD
8/28/202519.24 USD
8/27/202519.54 USD
8/26/202519.50 USD
8/25/202518.50 USD
8/22/202519.44 USD
8/21/202519.78 USD
8/20/202519.31 USD
Access this data via the Eulerpool API
Get Free API Key

Urogen Pharma Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
82.71 M USD
-62.06 M USD
-102.24 M USD
Jan 1, 2024
90.40 M USD
-96.78 M USD
-126.87 M USD
Jan 1, 2025
109.79 M USD
-125.53 M USD
-153.49 M USD
Jan 1, 2026 (e)
322.20 M USD
-262.68 M USD
-11.69 M USD
Jan 1, 2027 (e)
541.49 M USD
-411.18 M USD
134.45 M USD
Jan 1, 2028 (e)
576.89 M USD
-548.07 M USD
170.89 M USD
Jan 1, 2029 (e)
710.44 M USD
-674.96 M USD
271.37 M USD
Jan 1, 2030 (e)
840.40 M USD
-798.43 M USD
343.31 M USD

Urogen Pharma Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 19, 2026, 4:19 PM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
–17.008.001.00–11.0048.0064.0082.0090.00109.00322.00541.00576.00710.00840.00
––-52.94-87.50––336.3633.3328.139.7621.11195.4168.016.4723.2618.31
–100.0087.509,700.00–90.9187.5087.5089.0290.0088.9988.9988.9988.9988.9988.99
97.0017.007.0097.0097.0010.0042.0056.0073.0081.0097.00286.55481.44512.59631.83747.52
-12.00–-19.00-77.00-109.00-126.00-92.00-79.00-62.00-96.00-125.00-262.00-411.00-548.00-674.00-798.00
––-237.50-7,700.00–-1,145.45-191.67-123.44-75.61-106.67-114.68-81.37-75.97-95.14-94.93-95.00
-12.00-1.00-20.00-75.00-105.00-128.00-110.00-109.00-102.00-126.00-153.00-11.00134.00170.00271.00343.00
200.00-91.671,900.00275.0040.0021.90-14.06-0.91-6.4223.5321.43-92.81-1,318.1826.8759.4126.57
2.3010.9613.6116.2121.1622.1522.4323.0936.1547.0349.2349.2349.2349.2349.2349.23
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Urogen Pharma generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Urogen Pharma retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Urogen Pharma's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Urogen Pharma has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Urogen Pharma's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Urogen Pharma stock margins

The Urogen Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Urogen Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Urogen Pharma.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
89.27 %
-192.11 %
-230.67 %
Jan 1, 2022
88.11 %
-122.82 %
-170.58 %
Jan 1, 2023
88.68 %
-75.03 %
-123.61 %
Jan 1, 2024
90.18 %
-107.06 %
-140.35 %
Jan 1, 2025
88.66 %
-114.34 %
-139.81 %
Jan 1, 2026 (e)
88.66 %
-81.53 %
-3.63 %
Jan 1, 2027 (e)
88.66 %
-75.93 %
24.83 %
Jan 1, 2028 (e)
88.66 %
-95.01 %
29.62 %

Urogen Pharma Stock Revenue, EBIT, Earnings per Share

The Urogen Pharma earnings per share therefore indicates how much revenue Urogen Pharma has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
2.14 USD
-4.11 USD
-4.94 USD
Jan 1, 2022
2.79 USD
-3.42 USD
-4.75 USD
Jan 1, 2023
2.29 USD
-1.72 USD
-2.83 USD
Jan 1, 2024
1.92 USD
-2.06 USD
-2.70 USD
Jan 1, 2025
2.23 USD
-2.55 USD
-3.12 USD
Jan 1, 2026 (e)
6.70 USD
-5.34 USD
-0.24 USD
Jan 1, 2027 (e)
11.25 USD
-8.35 USD
2.79 USD
Jan 1, 2028 (e)
11.99 USD
-11.13 USD
3.55 USD

Urogen Pharma business model & stock analysis

Urogen Pharma Ltd is a biopharmaceutical company specializing in the development and marketing of innovative therapies for urological diseases. The company was founded in Israel in 2004 and is headquartered in Ra'anana. Answer: Urogen Pharma Ltd is a biopharmaceutical company specializing in the development and marketing of innovative therapies for urological diseases.

Urogen Pharma SWOT Analysis

Strengths

Urogen Pharma Ltd has a strong portfolio of innovative pharmaceutical products.

The company has a dedicated and experienced team of researchers and scientists.

Urogen Pharma Ltd has built strong relationships with healthcare providers and distributors.

Weaknesses

The company faces intense competition in the pharmaceutical industry.

Urogen Pharma Ltd has limited presence in international markets.

There are certain regulatory challenges that the company needs to navigate.

Opportunities

Increasing demand for pharmaceutical products globally presents growth opportunities.

Exploring strategic partnerships or collaborations can provide access to new markets.

The company can expand its product portfolio to cater to a wider range of medical conditions.

Threats

Changing regulatory landscape and policies can impact the company's operations.

Intense competition from established pharmaceutical companies poses a threat.

Economic downturns or market uncertainties may affect the company's growth prospects.

Urogen Pharma Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Urogen Pharma Employees
Details
Date
Urogen Pharma Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Urogen Pharma Segments

Urogen Pharma Revenue by Segment (1/2)

  • 3 Years

  • Max

Jelmyto
Zusduri
Details
Date
Jelmyto
Zusduri
Jan 1, 2021
48.04 M USD
0.00 USD
Jan 1, 2022
64.36 M USD
0.00 USD
Jan 1, 2023
82.71 M USD
0.00 USD
Jan 1, 2024
90.40 M USD
0.00 USD
Jan 1, 2025
0.00 USD
15.80 M USD

Urogen Pharma Revenue by Segment (2/2)

  • Max

Jelmyto
Details
Date
Jelmyto
Jan 1, 2021
0.00 USD
Jan 1, 2022
0.00 USD
Jan 1, 2023
0.00 USD
Jan 1, 2024
0.00 USD
Jan 1, 2025
93.99 M USD

Urogen Pharma Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Urogen Pharma historical P/E ratio, EBIT multiple, and P/S ratio

Urogen Pharma annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Urogen Pharma shares outstanding

The number of shares of Urogen Pharma was 49.23 M in 2025. This indicates how many shares Urogen Pharma is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
22.43 M Stocks
Jan 1, 2022
23.09 M Stocks
Jan 1, 2023
36.15 M Stocks
Jan 1, 2024
47.03 M Stocks
Jan 1, 2025
49.23 M Stocks
Jan 1, 2026 (e)
49.23 M Stocks
Jan 1, 2027 (e)
49.23 M Stocks
Jan 1, 2028 (e)
49.23 M Stocks

Current Urogen Pharma forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
85.71 % (12)
Hold
14.29 % (2)
Sell
0.00 % (0)
12M Price Target
34.68
Last Price
48.88
Currency
USD
12M Return Potential
-29.05 %
LTM Return
0 %

Urogen Pharma Analyst Rating Actions

DateFirmActionRatingReliability
7/21/2026
Guggenheim
Guggenheim
MaintainedBuy30
7/16/2026
Oppenheimer
Oppenheimer
MaintainedOutperform60
6/3/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
5/18/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
5/11/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
5/7/2026
Oppenheimer
Oppenheimer
MaintainedOutperform60
3/31/2026
D. Boral Capital
D. Boral Capital
MaintainedBuy–
3/2/2026
D. Boral Capital
D. Boral Capital
MaintainedBuy–
1/23/2026
D. Boral Capital
D. Boral Capital
MaintainedBuy–
1/5/2026
D. Boral Capital
D. Boral Capital
MaintainedBuy–

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Urogen Pharma Earnings Calls

2025

Urogen Pharma Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/6/2026-0.30USD-64.20 MUSD-2026 Q2
5/11/2026-0.49USD-45.72 MUSD-2026 Q1
3/12/2026-0.51USD-40.72 MUSD-2025 Q4
11/12/2024-0.83USD-24.69 MUSD-2024 Q3
5/9/2024-0.74USD-22.99 MUSD-2024 Q1
3/14/2024-0.69USD-23.02 MUSD-2023 Q4
11/8/2023-0.89USD-24.35 MUSD-2023 Q3
8/9/2023-0.80USD-26.74 MUSD-2023 Q2
5/8/2023-0.96USD-22.23 MUSD-2023 Q1
3/20/2023-1.03USD-20.59 MUSD-2022 Q4

EESG©

Eulerpool ESG Scorecard© for the Urogen Pharma stock

64/100
60
Environment
53
Social
78
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Urogen Pharma shareholder structure

% Name
9.44361%
RTW Investments L.P.
RTW Investments L.P.
9.44361%
RTW INVESTMENTS, LP
RTW INVESTMENTS, LP
9.29761%
Paradigm BioCapital Advisors LP
Paradigm BioCapital Advisors LP
5.91396%
BLACKROCK, INC.
BLACKROCK, INC.
5.43833%
TORONTO DOMINION BANK
TORONTO DOMINION BANK
5.32054%
MORGAN STANLEY
MORGAN STANLEY
...

Urogen Pharma Beneficial Ownership Filings (SEC 13D/G)

Free Float
88.7%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
11.33%
Menora Mivtachim Pensions and Gemel Ltd.
Menora Mivtachim Pensions and Gemel Ltd.
SEC ↗
9.99%
Rajeev Shah
Rajeev Shah
SEC ↗
9.99%
RA Capital Healthcare Fund, L.P.
RA Capital Healthcare Fund, L.P.
SEC ↗
9.99%
Peter Kolchinsky
Peter Kolchinsky
SEC ↗
8.87%
Robert Atchinson
Robert Atchinson
SEC ↗
8.87%
Phillip Gross
Phillip Gross
SEC ↗
8.51%
Mr. Ortav Yehudai
Mr. Ortav Yehudai
SEC ↗
8.51%
Great Point Partners, LLC
Great Point Partners, LLC
SEC ↗
8.51%
Dr. Jeffrey R. Jay, M.D.
Dr. Jeffrey R. Jay, M.D.
SEC ↗
6.53%
Moshe Arkin
Moshe Arkin
SEC ↗

Urogen Pharma Executives and Management Board

11 members · avg. age 62 · 27 % women

EB

Ms. Elizabeth Barrett (62)

President, Chief Executive Officer, Director · since 2019

4.15 M USD

Management

MS

Dr. Mark Schoenberg (67)

Chief Medical Officer

1.36 M USD
JS

Mr. Jason Smith (53)

Chief Compliance Officer, General Counsel, Corporate Secretary

1.28 M USD
CD

Mr. Christopher Degnan (45)

Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer

1.05 M USD
VP

Mr. Vincent Perrone

Investor Relations · since 2022

–

Board of Directors

AB

Dr. Arie Belldegrun (75)

Independent Chairman of the Board

331,911.00 USD
LW

Dr. Leana Wen (42)

Independent Director

196,421.00 USD
DW

Mr. Daniel Wildman (68)

Independent Director

194,302.00 USD
CB

Ms. Cynthia Butitta (70)

Independent Director

193,922.00 USD
SH

Dr. Stuart Holden (82)

Independent Director

186,422.00 USD
JR

Mr. James Robinson (55)

Independent Director

183,922.00 USD

Urogen Pharma Supply Chain

Urogen Pharma Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
3 companies
#Nameβ 1YTrend
1
Teva Pharmaceutical Inds
Supplier·IL
-0.77
0.11
0.18
0.06
0.62
0.69
—
2
Agenus
Supplier·Customer·Biotechnology·US
0.38
0.76
0.78
0.74
0.90
0.43
—
#Nameβ 1YTrend
1
AbbVie
Supplier·Customer·Biotechnology·US
0.36
0.83
-0.14
-0.55
-0.84
-0.88
-0.17

Frequently asked questions about Urogen Pharma

The business model of Urogen Pharma Ltd revolves around developing and commercializing innovative therapies for various urological conditions. Urogen Pharma primarily focuses on developing novel treatments for patients with urinary tract cancers and other urological disorders. The company utilizes its proprietary technology platform to create locally administered, precision medicines that aim to deliver targeted therapy where it is needed most while minimizing side effects. By leveraging its expertise in urology and utilizing advanced scientific techniques, Urogen Pharma strives to improve patient outcomes and quality of life by providing effective and tailored treatment options for urological conditions.

Urogen Pharma Ltd is primarily active in the pharmaceutical industry.

The main competitors of Urogen Pharma Ltd in the market include various pharmaceutical companies that specialize in the same therapeutic areas. Some notable competitors are Company A, Company B, and Company C. These companies also develop and market pharmaceutical products for similar indications as Urogen Pharma Ltd. However, Urogen Pharma Ltd distinguishes itself through its unique approach to drug development and its focus on innovation. Despite the competition, Urogen Pharma Ltd strives to maintain its position as a leading player in the market by continuously advancing its pipeline and delivering high-quality products to patients.

Urogen Pharma Ltd is a pharmaceutical company specializing in developing innovative therapies for urologic conditions. Founded in 2004, the company is headquartered in Israel. Urogen Pharma is dedicated to improving patients' lives by providing novel treatment options in the field of urology. With a focus on urothelial cancer and urinary tract infections, Urogen Pharma's research and development efforts aim to address unmet medical needs. The company has achieved significant milestones, including the approval of their first therapy, Jelmyto, by the U.S. Food and Drug Administration in 2020. Urogen Pharma continues to expand its pipeline and collaborate with renowned scientific and medical professionals to transform urologic care.

Urogen Pharma Ltd has achieved several significant milestones. The company successfully received FDA approval for its innovative drug, UGN-101, which offers a promising treatment option for patients with low-grade upper tract urothelial cancer. Urogen has also expanded its product portfolio and secured major collaborations with renowned pharmaceutical companies. In addition, the company has demonstrated strong financial performance, with consistent revenue growth and strategic investments in research and development. Urogen Pharma Ltd's dedication to innovation and commitment to improving patient outcomes have positioned the company as a leader in the pharmaceutical industry.

Urogen Pharma Ltd is primarily present in the United States, with its headquarters located in Princeton, New Jersey. The company focuses on developing innovative treatments for urological diseases and cancers. Urogen Pharma Ltd has a strong presence in various regions of the United States, including major cities like New York, Chicago, and Los Angeles. With their commitment to improving patient outcomes, Urogen Pharma Ltd continues to expand its reach and collaborate with healthcare professionals and organizations nationwide.

Urogen Pharma Ltd is a biopharmaceutical company committed to advancing innovative therapies for urological conditions. With a strong dedication to improving patients' lives, Urogen Pharma focuses on developing novel treatments that address significant unmet medical needs. The company's corporate philosophy revolves around excellence, integrity, and scientific rigor. By harnessing cutting-edge technology and expertise, Urogen Pharma strives to deliver transformative solutions to patients worldwide. With its unwavering commitment to scientific advancement and patient-centric approach, Urogen Pharma continues to drive progress in the field of urology.

Analysts currently set an average price target of 35.96 USD for the Urogen Pharma stock (median: 34.68 USD), implying -26.4 % versus the latest price. The consensus is based on 14 analyst ratings.

Urogen Pharma Analyst Price Targets 2026

14 analysts currently rate the Urogen Pharma stock: 12 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Urogen Pharma to generate revenue of 322.20 M USD and earnings per share of -0.24 USD.

Urogen Pharma Analyst Price Targets 2026

Converted at the current exchange rate, the Urogen Pharma share trades at 41.66 EUR (48.22 USD).

The Urogen Pharma share (URGN) is listed on 3 stock exchanges, including: NASDAQ (URGN), Frankfurt (UR8.F), London (0XOD.L).

Urogen Pharma Ltd is a biopharmaceutical company that specializes in developing novel therapeutics for urological and oncological diseases. The company is based in the USA and has a global network of research and development partners. Urogen Pharma's business model includes several divisions, including research and development, manufacturing, and distribution of innovative drugs. The company specializes in developing drugs tailored to the needs of urological and oncological patients. The product range currently includes two preparations: Jelmyto™ and UGN-102. Jelmyto™ is the first and only intravesical chemotherapeutic for the treatment of superficial, non-muscle invasive tumors of the ureter. The treatment of ureteral tumors is difficult as they are typically challenging to reach and chemotherapy is usually ineffective for treating deep-seated tumors. Jelmyto™ works through direct intra-ureteral instillation and has proven to be highly effective in reducing tumor burden. UGN-102 is an innovative drug for the treatment of bladder cancer based on extensive research. The active ingredient is injected directly into the bladder and aims to destroy cancer cells without affecting healthy cells. UGN-102 is currently in Phase 3 clinical trials and has the potential to be a groundbreaking new treatment option for bladder cancer patients. In addition to product development, Urogen Pharma also invests in the manufacturing and distribution of its drugs. The company has agreements with leading contract manufacturing organizations for the production of its products and collaborates with some of the world's leading hospitals to distribute its products. Urogen Pharma's business model is based on ongoing development and innovation of new therapies for urological and oncological diseases. The company relies on close collaboration with leading research institutions and investments in the manufacturing and distribution of its products to achieve its vision of a better patient experience.

The expected revenue of Urogen Pharma is 322.20 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Urogen Pharma is -11.69 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Urogen Pharma is currently -203.11. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Urogen Pharma stock.

The price-to-sales ratio (P/S) of Urogen Pharma is currently 7.37. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Urogen Pharma stock.

The Eulerpool Quality Score for Urogen Pharma is 3/10.

The ISIN of Urogen Pharma is IL0011407140. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Urogen Pharma is A2DTCV. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Urogen Pharma is URGN. The ticker symbol is used to trade Urogen Pharma shares on the stock exchange.

Urogen Pharma paid dividends every year for the past 0 years.

Urogen Pharma is assigned to the 'Health' sector.

The dividends of Urogen Pharma are distributed in USD.

All fundamentals and in-depth analysis of Urogen Pharma

Our stock analysis for Urogen Pharma stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Urogen Pharma. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Urogen Pharma Stock
Urogen Pharma Revenue→
Urogen Pharma Stock
Urogen Pharma Net Income→
Urogen Pharma Stock
Urogen Pharma P/E→
Urogen Pharma Stock
Urogen Pharma P/S→
Urogen Pharma Stock
Urogen Pharma EBIT→
Urogen Pharma Stock
Urogen Pharma Dividend→
Urogen Pharma Stock
Urogen Pharma Directors Dealings→
Urogen Pharma Stock
Urogen Pharma Stocks→
Urogen Pharma Stock
Urogen Pharma Market capitalization→
Urogen Pharma Stock
Urogen Pharma Debt→
Urogen Pharma Stock
Urogen Pharma Liabilities→
Urogen Pharma Stock
Urogen Pharma Equity→
Urogen Pharma Stock
Urogen Pharma AAQS→
Urogen Pharma Stock
Urogen Pharma Employees→
Urogen Pharma Stock
Urogen Pharma ROE→
Urogen Pharma Stock
Urogen Pharma ROA→
Urogen Pharma Stock
Urogen Pharma ROCE→
Urogen Pharma Stock
Urogen Pharma News→
Urogen Pharma Stock
Urogen Pharma Analyst Price Targets→

Health Stocks

UrtesteUpstream BioUS Physical TherapyUpHealthUS Stem CellUniverse PharmaceuticalsUscomUniversal Vision Biotechnology CoUtah Medical ProductsUniversal Health ServicesVaccinexUniversal Health International Group HoldingAll Stocks A–Z →